Spero Therapeutics, Inc. SPRO
Spero Therapeutics, Inc. statistics & valuation
Market cap$130.9M
P / E15.3×
P / S2.0×
P / B2.2×
Net margin12.8%
Return on equity14.5%
Return on capital10.5%
Graham number +54.4%$1.84
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($1.84); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 9.5% | -152.9% | 20.7% | -78.9% | -481.9% | -847.9% | -348.4% | -1079.3% | -2108.6% | -9916.7% |
| Net margin | 12.8% | -142.9% | 22.0% | — | -491.9% | -839.2% | -335.6% | -1051.4% | -1957.7% | -7609.3% |
| FCF margin | — | — | — | — | — | -922.1% | -277.4% | -1060.5% | -1977.7% | -8892.2% |
| Return on assets | 12.4% | -62.0% | 12.5% | — | -52.5% | -51.0% | -57.4% | -32.3% | -41.4% | -185.1% |
| Return on equity | 14.5% | -148.7% | 21.3% | — | -101.7% | -59.3% | -81.7% | -36.0% | -45.6% | 51.8% |
| Current ratio | 7.59 | 2.19 | 3.53 | 5.25 | 8.46 | 9.70 | 3.58 | 10.08 | 11.29 | 1.72 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.